Abstract:Platinum chemotherapy drugs, represented by cisplatin, have been widely used in cancer therapy. While they are effective, their use is limited by their adverse effects in long-term administration, especially the lack of selectivity and high systemic toxicity. Encouragingly, molecular-like platinum nanoclusters, as a bridge between nanomedical and small molecular drugs, provide an attractive opportunity to completely change the current status of cancer treatment, mainly due to their unique structural advantages, making them highly efficient and low toxic. Functional modifications offer a promising avenue to enhance template-modified platinum nanoclusters' selectivity and safety, addressing systemic toxicity concerns. Concurrently, leveraging tumor heterogeneity facilitates drug bioactivity via metabolism, thereby augmenting therapeutic efficacy. Herein, we utilized iRGD-modified bovine serum albumin (BSA-iRGD) as the protective molecule to construct platinum nanoclusters drug (PtNC@BSA-iRGD) directly under mild conditions. The new type of chemotherapeutic drug PtNC@BSA-iRGD exhibits excellent antitumor activity in vitro/vivo, in comparison to clinical commercial first-line carboplatin. This powerful antitumor effect is attributed to its selective uptake by tumor cells through receptor-mediated endocytosis. The release of platinum ions inhibits DNA replication by forming DNA-Pt complexes, activates apoptosis pathways, and ultimately induces tumor cell apoptosis. More impressively, compared to first-line platinum chemotherapy drugs, PtNC@BSA-iRGD has superior biocompatibility while possessing higher tumor inhibitory activity in vivo during medication treatment. This feature compensates for the shortcomings of clinical chemotherapy platinum-based drugs. This study provides novel insights into exploring new forms of metal cluster-based platinum drugs with high efficiency for optimizing therapeutic efficacy while minimizing systemic toxicity.

Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Ultrasound-Enhanced Reactive Oxygen Species Responsive Charge-Reversal Polymeric Nanocarriers for Efficient Pancreatic Cancer Gene Delivery.

Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species

Ultrasmall Platinum Nanoclusters: A Potent Chemotherapeutic Drug for Cancer-Specific DNA Damage with Optimizing Therapeutic Efficacy While Minimizing Systemic Toxicity

Platinum-based nanocomposites loaded with MTH1 inhibitor amplify oxidative damage for cancer therapy

Polymeric Nanoparticles with ROS‐Responsive Prodrug and Platinum Nanozyme for Enhanced Chemophotodynamic Therapy of Colon Cancer

A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy

A Platinum-Ruthenium Hybrid Prodrug with Multi-Enzymatic Activities for Chemo-Catalytic Therapy of Hypoxic Tumors

Blood-triggered Generation of Platinum Nanoparticle Functions As an Anti-Cancer Agent

Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy

Cancer cell membrane-camouflaged CuPt nanoalloy boosts chemotherapy of cisplatin prodrug to enhance anticancer effect and reverse cisplatin resistance of tumor

Toxic Reactive Oxygen Species Enhanced Synergistic Combination Therapy by Self‐Assembled Metal‐Phenolic Network Nanoparticles

Platinum Based Theranostics Nanoplatforms for Antitumor Applications.

Reactive Oxygen Species-Activated Self-Accelerated Drug Release Nanoparticles for Enhanced Cancer Combination Therapy

Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy

Platinum Prodrug Nanoparticles with COX‐2 Inhibition Amplifies Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

Mitochondria-acting Carrier-Free Nanoplatform Self-Assembled by Α-Tocopheryl Succinate Carrying Cisplatin for Combinational Tumor Therapy

A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance

Induction of immunogenic cell death by novel platinum-based anticancer agents